dupilumab

Details

Files
Generic Name:
dupilumab
Project Status:
Active
Therapeutic Area:
Chronic rhinosinusitis with nasal polyps
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0878-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​As add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openNovember 07, 2024
Call for patient/clinician input closedJanuary 06, 2025
Submission receivedDecember 18, 2024
Submission acceptedJanuary 09, 2025
Review initiatedJanuary 10, 2025
Draft CADTH review report(s) provided to sponsor for commentMarch 28, 2025
Deadline for sponsors commentsApril 08, 2025
CADTH review report(s) and responses to comments provided to sponsorMay 15, 2025
Expert committee meeting (initial)May 28, 2025
Draft recommendation issued to sponsorJune 09, 2025
To
June 11, 2025
Draft recommendation posted for stakeholder feedbackJune 19, 2025
End of feedback periodJuly 04, 2025